RxDoctor Payments Data

Mark Sperry, MD

Internal Medicine · Boston, MANPI 1376773754

Payments from drug & device makers

$480in general payments, 2019–2025

Across 22 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$93
  • Merck$85
  • Pfizer$75
  • Insmed, Inc.$70
  • Johnson & Johnson$61
  • Vapotherm Inc$38
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$46397%
  • Education$163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$480 in reported general payments places this provider in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$43,710
Medicare patients
251
Services billed
585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter527$361,006
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr395$196,508
Stiolto RespimatTiotropium Br/Olodaterol Hcl136$67,755
Breo ElliptaFluticasone/Vilanterol105$50,199
Spiriva RespimatTiotropium Bromide62$32,945
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$17,418
Incruse ElliptaUmeclidinium Bromide42$16,674
Bevespi AerosphereGlycopyrrolate/Formoterol Fum33$13,848
Albuterol Sulfate HfaAlbuterol Sulfate302$9,182
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$8,432
SymbicortBudesonide/Formoterol Fumarate20$6,817
Advair HfaFluticasone Propion/Salmeterol18$6,490
Ventolin HfaAlbuterol Sulfate113$6,164
Roflumilast25$2,422
Advair DiskusFluticasone Propion/Salmeterol12$2,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$18$624,3881,069 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →